title: Metabolic syndrome in patients with prostate cancer undergoing androgen suppression.
abstract: OBJECTIVE
  Cardiovascular mortality is the leading cause of death in patients with prostate cancer (PC), metabolic syndrome (MS) being related to it. The main objective of this study was to determine the prevalence of MS in patients with CP undergoing androgen suppression (AS).
  
  
  METHODS
  We performed a retrospective study of cases and controls that included 159 patients. The study group was made up of 53 patients with PC undergoing SA for a period exceeding 12 months. The control group was formed by 53 patients with PC at the time of diagnosis and 53 patients with negative prostate biopsy. All patients were evaluated for presence of MS according to NCEP-ATPIII criteria.
  
  
  RESULTS
  Prevalence of MS in patients without PC was 32.1% and in those with non-treated PC 35.8%, P = .324. In patients with PC undergoing AS, prevalence of MS was 50.9%, P < .001. When AS duration was less than 36 months, prevalence of MS was 44.0% and when greater than 36 months 57.1%, P < .001. Waist circumference and hyperglycemia were the two MS components that significantly increased. AS and its duration were independent predictors factors for the development of MS.
  
  
  CONCLUSIONS
  Continuous AS therapy increases the prevalence of MS and especially waist circumference and hyperglycemia. Development of MS increases according to AS duration.
authors.affiliation: Servicio de Urología, Hospital Vall d́Hebron, Universitat Autonoma de Barcelona, Barcelona, España. Electronic address: jmorote@vhebron.net.
authors.forename: J
authors.initials: J
authors.lastname: Morote
authors.affiliation: Servicio de Urología, Hospital Vall d́Hebron, Universitat Autonoma de Barcelona, Barcelona, España.
authors.forename: J
authors.initials: J
authors.lastname: Ropero
authors.affiliation: Servicio de Urología, Hospital Vall d́Hebron, Universitat Autonoma de Barcelona, Barcelona, España.
authors.forename: J
authors.initials: J
authors.lastname: Planas
authors.affiliation: Servicio de Urología, Hospital Vall d́Hebron, Universitat Autonoma de Barcelona, Barcelona, España.
authors.forename: A
authors.initials: A
authors.lastname: Celma
authors.affiliation: Servicio de Urología, Hospital Vall d́Hebron, Universitat Autonoma de Barcelona, Barcelona, España.
authors.forename: J
authors.initials: J
authors.lastname: Placer
authors.affiliation: Servicio de Bioquímica, Hospital Vall d́Hebron, Universitat Autonoma de Barcelona, Barcelona, España.
authors.forename: R
authors.initials: R
authors.lastname: Ferrer
authors.affiliation: Servicio de Anatomía Patológica, Hospital Vall d́Hebron, Universitat Autonoma de Barcelona, Barcelona, España.
authors.forename: I
authors.initials: I
authors.lastname: de Torres
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D016022:Case-Control Studies; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000453:epidemiology*; D008875:Middle Aged; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D000726:Androgen Antagonists
keywords: Androgen suppression; Cáncer de próstata; Metabolic syndrome; Prostate cancer; Supresión androgénica; Síndrome metabólico